To me the biggest concern is that these companies appear to be promoting a lifelong duration of therapy, as evident by their zero attention to getting people off the drugs, without reverting back for both weight gain and risk of adverse outcomes
As someone closely involved in diabetes and obesity care, I really appreciate how clearly you bring out the balance between innovation, affordability, and long-term access to GLP-1 therapies
Increased market competition could reduce prices and improve access, although manufacturing complexity may limit how low prices fall initially
doi:10.1016/j.jpba.2008.05.037 Lu Z, Liu N, Huang H, et al
PubMed laboratory research record [PMID: 40755669] PubMed record related to this compound for laboratory literature review
What states does Levity serve for GLP-1 treatment